Skip to main content

Table 2 Patients’ characteristics according to drug adherence

From: Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?

VARIABLE

Discontinuated patients

Adherent patients

Standardized difference (%) *

Mean age (± SD)

70.15 (9.6)

70.37 (9.34)

-

Age class

   

 40–55

762 (6.21)

937 (5.86)

−1.4916

 56–65

3131 (25.52)

3870 (24.18)

−3.0886

 66–75

4784 (38.99)

6336 (39.59)

1.2350

 76–85

2936 (23.93)

4118 (25.73)

4.1775

 >85

657 (5.35)

742 (4.64)

−3.2957

 Previous hospitalization for BPH

560 (4.56)

752 (4.70)

0.6430

 Previous BPH surgery

45 (0.37)

53 (0.33)

−0.6030

 Previous BPH severity factors

392 (3.19)

462 (2.89)

−1.7928

 Previous BPH related therapy

7155 (58.31)

9336 (58.34)

0.0529

Therapeutic regimen

   

  AB

10923 (89.02)

13703 (85.63)

−10.2158

  5ARI

1050 (8.56)

1259 (7.87)

−2.5140

  CT

297 (2.42)

1041 (6.51)

19.8785

  1. Legend: AB: Alpha-blocker monotherapy; 5ARI; 5-alpha reductase inhibitors monotherapy; CT: Combination Therapy; * Standardized difference greater than 10 % represents meaningful imbalance in explored variable between treatment groups